Girish Mahajan

ABT 418

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
CAS Number  147402-53-7
ChemSpider  106627
Formula  C9H14N2O
PubChem CID  119380
ChEMBL  CHEMBL274525
Molar mass  166.22
ABT-418

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not the α3β4 subtype familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.

References

ABT-418 Wikipedia


Similar Topics
Leslie, My Name Is Evil
David Bradley (UK journalist)
Rémy Noë
Topics